论文部分内容阅读
作者报道18例骨髓纤维化(MF)患者PAIgG和PAIgM测定之结果。全组病例均符合特发性骨髓纤维化(IMF)诊断标准,其中,1例急性骨髓纤维化综合征(AMF),5例过渡型骨髓增殖性疾病(TMD),1例真性红细胞增多性骨髓纤维化衰竭期。10例经常发热但无明确感染,近期需要细胞毒药物治疗而确定为活动期。作本研究时,3例用强的松龙治疗,无1例接受细胞毒药物治疗或新近有感染。PAIg测定采用酶联免疫吸附试验(ELISA),20例健康对照者PA-IgG 0.00-0.21 A405(10~7h)~(-1)(中数0.06,95%置信限0.01-0.16)。PAIgM0.00-0.06A405(10~7h)~(-1)
The authors report the results of PAIgG and PAIgM assays in 18 patients with myelofibrosis (MF). All the cases were in line with the diagnostic criteria of idiopathic myelofibrosis (IMF), including 1 case of acute myelofibrosis syndrome (AMF), 5 cases of transitional myeloproliferative disease (TMD), 1 case of polycythemia vera Fibrosis failure period. 10 cases of fever but no definite infection, the recent need for cytotoxic drug treatment was identified as active period. In this study, 3 patients were treated with prednisolone and none of them received cytotoxic drug treatment or had a recent infection. PAIg was determined by enzyme-linked immunosorbent assay (ELISA), PA-IgG was 0.00-0.21 A405 (10-7h) -1 (median 0.06, 95% confidence interval 0.01-0.16) of 20 healthy controls. PAIgM0.00-0.06A405 (10 ~ 7h) ~ (-1)